JPWO2021154929A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021154929A5 JPWO2021154929A5 JP2022546004A JP2022546004A JPWO2021154929A5 JP WO2021154929 A5 JPWO2021154929 A5 JP WO2021154929A5 JP 2022546004 A JP2022546004 A JP 2022546004A JP 2022546004 A JP2022546004 A JP 2022546004A JP WO2021154929 A5 JPWO2021154929 A5 JP WO2021154929A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- per week
- kras
- administered
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062968615P | 2020-01-31 | 2020-01-31 | |
| US62/968,615 | 2020-01-31 | ||
| US202063115433P | 2020-11-18 | 2020-11-18 | |
| US63/115,433 | 2020-11-18 | ||
| PCT/US2021/015401 WO2021154929A1 (en) | 2020-01-31 | 2021-01-28 | Combination therapy for treating abnormal cell growth |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023513015A JP2023513015A (ja) | 2023-03-30 |
| JP2023513015A5 JP2023513015A5 (https=) | 2024-01-22 |
| JPWO2021154929A5 true JPWO2021154929A5 (https=) | 2024-01-22 |
Family
ID=77079417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022546004A Pending JP2023513015A (ja) | 2020-01-31 | 2021-01-28 | 異常な細胞成長を処置するための併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230103007A1 (https=) |
| EP (1) | EP4096671A4 (https=) |
| JP (1) | JP2023513015A (https=) |
| KR (1) | KR20230011908A (https=) |
| CN (1) | CN115279376A (https=) |
| AU (1) | AU2021213753A1 (https=) |
| BR (1) | BR112022015161A2 (https=) |
| CA (1) | CA3168648A1 (https=) |
| IL (1) | IL295117A (https=) |
| MX (1) | MX2022009347A (https=) |
| WO (1) | WO2021154929A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| AU2020388848A1 (en) | 2019-11-18 | 2022-05-26 | Inxmed (Nanjing) Co., Ltd. | Use of FAK inhibitor in preparation of drug for treating tumors having NRAS mutation |
| JP7582694B2 (ja) | 2020-01-10 | 2024-11-13 | イミューニヤリング コーポレーション | Ｍｅｋ阻害剤及びその治療的使用 |
| MX2022009612A (es) | 2020-02-05 | 2022-09-19 | Inxmed Nanjing Co Ltd | Combinacion de bi853520 con farmacos quimioterapeuticos. |
| TW202206425A (zh) * | 2020-08-03 | 2022-02-16 | 大陸商應世生物科技（南京）有限公司 | 化合物的固體形式 |
| EP4284370A4 (en) * | 2021-01-29 | 2024-12-11 | Mirati Therapeutics, Inc. | POLYTHERAPIES |
| EP4346826A4 (en) * | 2021-05-27 | 2025-04-30 | Mirati Therapeutics, Inc. | COMBINATION THERAPIES |
| TW202313044A (zh) | 2021-08-16 | 2023-04-01 | 大陸商應世生物科技（南京）有限公司 | Ｉｎ１００１８與ｐｌｄ的聯用 |
| CN114133355B (zh) * | 2021-11-29 | 2023-09-15 | 郑州大学第一附属医院 | 一种2-苯基-1h-苯并咪唑类衍生物及其应用 |
| JP2024545147A (ja) * | 2021-12-10 | 2024-12-05 | ▲應▼世生物科技（南京）有限公司 | 腫瘍治療の医薬組合せ及び使用 |
| WO2023108110A2 (en) * | 2021-12-10 | 2023-06-15 | Verastem, Inc. | Combination therapy for treating abnormal cell growth |
| EP4488272A4 (en) * | 2022-02-28 | 2026-02-25 | Wigen Biomedicine Tech Shanghai Co Ltd | COMPOUND USED AS A FAK INHIBITOR AND ITS USE |
| US20250262194A1 (en) * | 2022-04-20 | 2025-08-21 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical for treating or preventing cancer |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| WO2023246869A1 (zh) * | 2022-06-24 | 2023-12-28 | 应世生物科技(南京)有限公司 | 治疗肿瘤的药物组合及用途 |
| KR20250052367A (ko) * | 2022-08-24 | 2025-04-18 | 인엑스메드 (난징) 컴퍼니 리미티드 | Fak 억제제와 미세소관 억제제의 약제학적 병용물 및 이의 용도 |
| CN119947725A (zh) * | 2022-09-30 | 2025-05-06 | 应世生物科技(南京)有限公司 | Fak抑制剂及诱导免疫原性细胞死亡的物质的药物组合及用途 |
| KR20250152577A (ko) * | 2023-01-06 | 2025-10-23 | 에라스카, 아이엔씨. | Raf 억제제 및 kras g12c 억제제 조합 요법 |
| CN115845065A (zh) * | 2023-01-09 | 2023-03-28 | 江苏省原子医学研究所 | Fn/fak通路抑制剂在制备提高甲状腺癌放射性碘治疗敏感性的药物中的用途 |
| US12254987B2 (en) * | 2023-03-23 | 2025-03-18 | Certis Oncology Solutions, Inc. | Artificial intelligence for identifying one or more predictive biomarkers |
| TW202440114A (zh) * | 2023-03-31 | 2024-10-16 | 大陸商應世生物科技（南京）有限公司 | 提高大分子藥物在腫瘤組織中的濃度的方法 |
| WO2025079712A1 (ja) * | 2023-10-12 | 2025-04-17 | 中外製薬株式会社 | ドライバー変異を有するがん患者における分子標的薬併用療法 |
| WO2025106901A1 (en) * | 2023-11-17 | 2025-05-22 | Quanta Therapeutics, Inc. | Combination cancer therapies with a kras modulator and an rtk-mapk pathway inhibitor |
| CN120284923A (zh) * | 2024-01-11 | 2025-07-11 | 四川弘合生物科技有限公司 | 一种包含榄香烯和激酶抑制剂的药物 |
| WO2025157162A1 (zh) * | 2024-01-22 | 2025-07-31 | 应世生物科技(南京)有限公司 | Fak抑制剂与kras g12c抑制剂的联用 |
| WO2025261307A1 (zh) * | 2024-06-17 | 2025-12-26 | 首药控股(北京)股份有限公司 | 治疗肿瘤的药物组合及用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6835472B2 (ja) * | 2013-03-05 | 2021-02-24 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | 癌の処置のための組成物 |
| ES2779975T3 (es) * | 2014-02-07 | 2020-08-21 | Verastem Inc | Métodos y composiciones para tratar el crecimiento celular anormal |
| JP2018519327A (ja) * | 2015-06-29 | 2018-07-19 | ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ． | 治療用組成物、組合せ物および使用の方法 |
| US11286469B2 (en) * | 2017-11-09 | 2022-03-29 | Wisconsin Alumni Research Foundation | Combination chemotherapy for the treatment of cancer |
| US20200038513A1 (en) * | 2018-07-26 | 2020-02-06 | Arvinas Operations, Inc. | Modulators of fak proteolysis and associated methods of use |
| JP7377679B2 (ja) * | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| CN114901286B (zh) * | 2019-11-27 | 2024-05-10 | 特普医药公司 | 涉及二芳基巨环化合物的组合疗法 |
-
2021
- 2021-01-28 CN CN202180012207.9A patent/CN115279376A/zh active Pending
- 2021-01-28 IL IL295117A patent/IL295117A/en unknown
- 2021-01-28 CA CA3168648A patent/CA3168648A1/en active Pending
- 2021-01-28 WO PCT/US2021/015401 patent/WO2021154929A1/en not_active Ceased
- 2021-01-28 AU AU2021213753A patent/AU2021213753A1/en active Pending
- 2021-01-28 BR BR112022015161A patent/BR112022015161A2/pt unknown
- 2021-01-28 EP EP21747362.8A patent/EP4096671A4/en active Pending
- 2021-01-28 JP JP2022546004A patent/JP2023513015A/ja active Pending
- 2021-01-28 KR KR1020227030021A patent/KR20230011908A/ko active Pending
- 2021-01-28 MX MX2022009347A patent/MX2022009347A/es unknown
- 2021-01-28 US US17/795,402 patent/US20230103007A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021154929A5 (https=) | ||
| EP4337191B1 (en) | Egfr inhibitor for the treatment of head and neck cancer | |
| CN115279376A (zh) | 用于治疗异常细胞生长的组合疗法 | |
| JP2017505321A5 (https=) | ||
| JP2021520406A5 (https=) | ||
| US20200009144A1 (en) | Combination Therapy Comprising Varlitinib and an Anticancer Agent | |
| JPWO2022015736A5 (https=) | ||
| JP2017537126A5 (https=) | ||
| TW200412937A (en) | Combination chemotherapy | |
| JPWO2022269525A5 (https=) | ||
| JP2021113228A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
| WO2025157162A1 (zh) | Fak抑制剂与kras g12c抑制剂的联用 | |
| JP2020536048A5 (https=) | ||
| CN119497618A (zh) | 药物组合产品以及组合疗法 | |
| JPWO2021222278A5 (https=) | ||
| WO2008035461A1 (fr) | Chimiothérapie adjuvante post-opératoire pour un cancer gastrique | |
| JPWO2019196764A5 (https=) | ||
| CN101357134A (zh) | 抗肿瘤效果增强剂和抗肿瘤剂 | |
| Sugawara et al. | Novel treatment of medullary thyroid cancer | |
| JPWO2023009572A5 (https=) | ||
| CN117959315B (zh) | 化合物pgg作为krasg12d抑制剂mrt1133的增效剂联合治疗胰腺癌的应用 | |
| JP2021503448A5 (https=) | ||
| CN112870366A (zh) | Ezh2抑制剂在制备治疗肿瘤药物中的新用途 | |
| CN112237586A (zh) | 重楼皂苷与索拉菲尼在制备抗肿瘤联用药物中的应用 | |
| CN112870365A (zh) | Ezh2抑制剂和/或parp抑制剂与化疗药物联合在制备治疗肿瘤药物中的用途 |